PharmaNutra also climbs the annual IQVIA ranking in number of products sold, coming twelfth out of more than 1700 Italian […]
Market Insight continues its in-depth study of PharmaNutra S.p.A. through interviews with Chairman and CEO, Roberto Lacorte, and Managing Director, […]
Great investor interest in the Company’s strategies during the virtual edition of the conference organised today by the Italian Stock […]
This has been a particularly symbolic year for PhamaNutra as 2020 marks two important anniversaries for two of the group’s […]
The No Doping Life association assigns the Play Sure Doping Free stamp to Cetilar® and ApportAL® products, and the company […]
Despite the COVID-19 emergency, the PharmaNutra Group is still strengthening its international presence through new trade agreements signed in Romania, […]
The innovative Sucrosomial® Magnesium developed by the PharmaNutra Group is one of the main ingredients of the new Multicentrum MyMAG […]
The Group recorded a significant +15% on the Italian market in the first three months of the current year, thanks […]
The Group obtains approval of the Cetilar® patent in the USA and new prospects unfold for SiderAL® in India thanks to […]
The Board of Directors approves the draft balance sheet and consolidated financial statement as of 31 December 2019. […]
As we all know, the spread of COVID-19 has led to a series of restrictive measures being taken by the […]
The Group will supply the products SiderAL® H and ApportAL® free of charge to the intensive care units of all […]